

1 Improved estimates of COVID-19 correlates of protection,
2 antibody decay and vaccine efficacy waning: a joint
3 modelling approach

4 Daniel J. Phillips¹, Maria D. Christodoulou¹, Shuo Feng^{2,3}, Andrew J. Pollard^{2,3},
5 Merryn Voysey^{2,3}, and David Steinsaltz¹

6 ¹Department of Statistics, University of Oxford, Oxford, UK

7 ²Oxford Vaccine Group, Department of Paediatrics, University of Oxford,
8 Oxford, UK

9 ³NIHR Oxford Biomedical Research Centre, Oxford, UK

10 July 2, 2024

11 **Abstract**

12 Reliable estimation of the relationship between COVID-19 antibody levels at the time of
13 exposure and the risk of infection is crucial to inform policy decisions on vaccination regimes.
14 We fit a joint model of anti-spike IgG antibody decay and risk of COVID-19 infection to data
15 from a randomized efficacy trial of the ChAdOx1 nCoV-19 vaccine. Our model improves
16 upon previous analyses by accounting for measurement error, decay in antibody levels and
17 variation between different individuals. We estimated correlates of protection, antibody
18 decay, and vaccine efficacy waning. Increased anti-spike IgG antibody levels at the time of
19 exposure correlate with increased vaccine-induced protection. We estimated vaccine efficacy
20 against symptomatic COVID-19 infection of 88.1% (95% CrI: 77.2, 93.6) at day 35, waning
21 to 60.4% (44.6, 71.0) at day 189 since the second dose. We report that longer intervals
22 between the first and second vaccine dose give lasting increased protection, and observe
23 lower efficacy in individuals aged ≥ 70 years from around 3 months after second dose. Our
24 methods can be used in future vaccine trials to help inform the timings and priority of
25 vaccine administration against novel diseases.

26 **Introduction**

27 Correlates of protection, i.e. immune markers which relate to the risk of a disease outcome, are
28 crucial to understanding the biological mechanisms for protection against infection after a given

29 treatment. Most studies consider how immune responses at a fixed time soon after treatment
30 correlate with risk of a disease outcome. However, it is the immune markers present at the time
31 of exposure which protect against infection. Modelling immune levels over time and relating
32 these to vaccine-induced protection, allows a clearer understanding of the relationship between
33 immune responses and protection, and avoids potential biases due to waning of immune levels
34 between the measurement and exposure. This further provides a natural framework to investi-
35 gate the effect of factors such as age, comorbidities and dose schedules on immune response and
36 protection, and to estimate changes in levels of protection over time.

37 In response to the COVID-19 pandemic, the (Oxford-AstraZeneca) ChAdOx1 nCoV-19 (AZD1222)
38 vaccine has been widely administered in the UK and worldwide, alongside other COVID-19 vac-
39 cines. Binding and neutralising antibodies have been shown to be correlates of protection for
40 ChAdOx1 nCoV-19 [1, 2] and other COVID-19 vaccines [3, 4, 5, 6, 7]. These studies all considered
41 how initial peak antibody responses correlate with the risk of future COVID-19 infection, as this
42 is the timepoint most relevant for vaccine licensure. If used to understand how antibody levels
43 at the time of exposure relate to risk of infection, the above approaches may be biased, as they
44 do not account for the waning of antibody levels between the time of the antibody measurement
45 and exposure [8]. Other studies focussed on the relationship between antibody levels at exposure
46 and the risk of subsequent infection [9, 10, 11]. Wei et al. (2022, 2023) used observational data
47 to estimate how risk of infection after vaccination relates to a recent antibody measurement
48 [9, 10]. However the use of observational data may cause their results to be biased. Follmann et
49 al. (2023) modelled antibody decay over time after vaccination, relating the risk of infection to
50 the predicted antibody level at the time of exposure [11]. However, Follmann et al. assume the
51 same rate of decay for all individuals, which may decrease power and lead to bias. Further, all
52 the above studies on correlates of protection use only one antibody measurement per individual.
53 This means they are unable to account for measurement error, which will likely introduce bias
54 to the results [12].

55 Vaccine efficacy (VE) has been shown to wane over time after two doses of the ChAdOx1 nCoV-
56 19, BNT162b2, and mRNA-1273 vaccines in the UK and elsewhere, against the Alpha variant
57 [13] and the Delta variant [13, 14, 15, 16, 17, 18]; as well as after a third booster dose [18, 19].
58 These studies all use observational data, in test-negative or cohort designs, which may intro-
59 duce bias due to unmeasured confounders affecting both the probability of vaccination and of
60 the clinical outcome (e.g. infection) [20, 21]. Randomised controlled trials are free of such bias,
61 however sample sizes tend to be much smaller, restricting power for analysis of efficacy waning.
62 Including antibody data in a model for vaccine efficacy waning may increase the power of the
63 analysis [22, 8].

64 Joint models of longitudinal and time-to-event data are a powerful tool to investigate how lon-
65 gitudinal biomarker trajectories relate to the risk of health- or disease-related events [8]. The
66 method has been applied to data on various diseases, especially disease progression in HIV/AIDS
67 [23] and cancer trials [8]. See Ibrahim, Chu and Chen (2010) [8] for an introductory review, and

68 Gould et al. (2015) [24] for a review with more detail on implementation methods and packages.
69 Joint modelling has been shown to reduce bias and increase power in estimating the relation-
70 ship between a longitudinal biomarker and clinical event [8, 25], when compared with methods
71 which use observed biomarkers directly to predict risk. This is because the approach accounts for
72 biomarker measurement error, as well as changes in the biomarker over time. Joint models have
73 been applied to understand how viral load [26] and changes in biomarkers [27] relate to risk of
74 mortality in COVID-19 patients, and to predict their risk of mortality from biomarker data [28].
75 They have also previously been used to understand how vaccine-induced immune responses relate
76 to risk of AIDS/death in HIV patients [29], and risk of relapse/death in cancer patients [30]. We
77 are not aware of any previous work applying joint modelling to understand how vaccine-induced
78 responses relate to risk of infection with COVID-19 or any other infectious disease.
79 We implement a two-stage joint model for COVID-19 antibody decay and risk of COVID-19 in-
80 fection after vaccination using multiple imputation [31]. Our model accounts for antibody decay
81 over time, individual differences in decay rates and antibody measurement error. We apply our
82 model to data from a randomised vaccine efficacy trial of two doses of the ChAdOx1 nCoV-19
83 vaccine [32, 33] to investigate three main outcomes (COV002). Firstly, we model the waning
84 of anti-spike IgG antibody levels over time. Secondly, we estimate correlates of protection -
85 the relationship between anti-spike IgG antibody levels at the time of exposure and the risk of
86 COVID-19 infection. Thirdly, we estimate waning vaccine efficacy over time, and investigate
87 covariate effects on antibody and vaccine efficacy waning.

88 Results

89 We used data from the COV002 trial [32, 33] to assess antibody waning, vaccine efficacy (VE)
90 waning, and correlates of protection against any COVID-19 infection and symptomatic COVID-
91 19 infection at the time of exposure. COV002 is a randomized single-blind vaccine efficacy trial of
92 the ChAdOx1 nCoV-19 vaccine, conducted in the United Kingdom. Participants were considered
93 at risk of infection from 21 days after their second dose of vaccine, over a period from 18 July
94 2020 to 30 June 2021. This analysis includes 4605 ChAdOx1 nCoV-19 vaccinated individuals
95 (vaccine arm) and 4423 individuals who received a MenACWY control vaccine (control arm).
96 Supplementary Table 1 summarises baseline characteristics for the vaccine and control arm.
97 Supplementary Fig. 1 summarises exclusions for the two groups. In the vaccine and control arm,
98 207 (4.5%) and 377 (8.5%) tested positive for COVID-19 respectively, and 71 (1.5%) and 217
99 (4.9%) were primary symptomatic COVID-19 cases respectively (Supplementary Table 1).

100 Waning anti-spike IgG antibody levels

101 Blood samples were taken at study visits in windows centred at 28 days, 90 days and 182 days
102 after the second dose. We refer to these as the PB28 (post-boost + 28 days), PB90 and PB182
103 study visits respectively. Samples were sent for anti-spike IgG antibody testing by case-cohort

104 sampling. Samples taken after a reported COVID-19 infection were excluded from analysis. Ob-
105 served antibody responses differed between those who did not return a positive COVID-19 test
106 during the at risk period (non-cases), all who later tested positive (cases) and those who tested
107 positive with primary symptoms (symptomatic cases). At the PB28, PB90 and PB182 study vis-
108 its, antibody observations were available from 1155 (26.3%), 519 (11.8%), 58 (1.3%) non-cases,
109 173 (83.6%), 64 (30.9%), 1 (0.5%) cases, and 59 (83.1%), 23 (32.4%), 1 (1.4%) symptomatic
110 cases respectively (Supplementary Table 2). At the PB28, PB90 and PB182 study visits, ob-
111 served antibody levels had a median (interquartile range (IQR)) of 219 (119, 383), 115 (66, 206),
112 65 (45, 117) BAU/mL among non-cases, 197 (103, 322), 93 (47, 168), 30 (NA – only one measure-
113 ment) BAU/mL among cases and 165 (100, 276), 78 (62, 178), 30 (NA – only one measurement)
114 BAU/mL among symptomatic cases respectively. Fig. 1a shows the observed antibody levels
115 against time, plotted on a log scale. The figure indicates (i) log antibody levels decay linearly,
116 (ii) different individuals have different levels of initial log antibody response and (iii) may have
117 different rates of decay.

118 In total, 923 antibody observations were available from 853 (18.5%) control participants. Among
119 control participants, antibody levels had a median (IQR) of 0.3 (< 0.21 (lower limit of quantifica-
120 tion (LLOQ)), 0.5) BAU/mL (Supplementary Fig. 2, Supplementary Table 2). In our subsequent
121 modelling we did not model antibody levels in the control arm, nor include an antibody effect
122 on risk for control participants.

123 We modelled the decay in antibody levels over time among the vaccinated participants, allowing
124 different initial antibody responses and rates of decay for different individuals (Methods). Pre-
125 dicted median anti-spike IgG levels at day 28, 90 and 182 were 217 (95% credible interval (CrI):
126 208, 227), 119 (113, 126), 49 (45, 54) BAU/mL respectively. The median half-life of the anti-spike
127 IgG antibody levels was 74 days (95% CrI: 69, 79). Fig. 1b shows the predicted antibody levels
128 over time for each individual in the study on a log-scale.

129 Predicted antibody levels and rates of decay varied among individuals. The estimated 25% and
130 75% quartiles for the antibody response at day 28 were given by 124 (95% CrI: 117, 130) and
131 378 (359, 398) respectively (Supplementary Fig. 9). The half-life of the antibody levels among
132 individuals in the study had an estimated 25% and 75% quartile of 62 days (95% CrI: 58, 67)
133 and 87 days (79, 96). Among non-cases, the median (IQR) predicted anti-spike IgG level at day
134 28 was 219 (95% CrI: 209, 229), among cases 192 (175, 209) and among symptomatic cases 169
135 (146, 196). The median half-life was 74 (95% CrI: 70, 79) among non-cases, 60 (52, 69) among
136 cases and 54 (45, 69) among symptomatic cases.

137 **Correlates of protection**

138 We modelled how the protective effect of the vaccine relates to the modelled antibody levels
139 over time. The instantaneous risk of COVID-19 infection for a given individual in our model
140 depends on: (i) the current background levels of COVID-19, (ii) covariates which may affect risk
141 of COVID-19 infection (iii) the modelled level of antibody 7 days prior, and (iv) a non-antibody




Figure 1: Observed and estimated anti-spike IgG antibody levels over time since vaccination. (a) Observed anti-spike IgG antibody levels over time since vaccination. Each point represents an observation, and consecutive observations from the same individual are connected by a line. Black, blue and red points represent observations taken at the PB28, PB90 and PB182 study visits respectively. The dashed horizontal line shows the lower limit of quantification (LLOQ), 0.21 BAU/mL. (b) The posterior mean estimate of the latent true antibody levels over time for each individual. Note 1b represent estimates of the latent true antibody levels which are free from measurement error, whereas the observed antibody levels in 1a are measured with error, so show higher variability.

142 effect due to vaccination (Methods). We assume a 7 day gap between initial exposure to COVID-
143 19 and a positive test being reported.

144 Supplementary Fig. 3-6 show an estimate of the baseline hazard of infection during the trial
145 period, the number of participants at risk over time since vaccination, the timings of antibody
146 samples, and the timings of COVID-19 infections in the study respectively. Differences in baseline
147 risk of infection due to different covariates are reported in Supplementary Fig. 7 and Supplemen-
148 tary Table 6.

149 We assessed how predicted antibody level at the time of exposure correlates with protection
150 against COVID-19 infection. Predicted anti-spike IgG titer was correlated with protection. Fig.
151 2 shows the relationship between VE and anti-spike IgG antibody level predicted by our model.
152 Anti-spike IgG values of 10, 100 and 1000 BAU/mL represent the 0.0%, 17.7% and 97.1% quan-
153 tiles of predicted antibody levels at day 28 post second dose, and the 5.4%, 78.1% and 100%
154 quantiles of predicted levels at day 182 respectively. At anti-spike IgG levels of 10, 100 and
155 1000 BAU/mL, the VE against symptomatic infection was 36.1% (95% CrI: -20.7, 63.0), 76.1%
156 (64.4, 88.7), 100% (97.3, 100) respectively. We observe lower efficacy against any COVID-19
157 infection at the same antibody levels, 14.3% (95% CrI: -22.5, 38.1), 55.3% (44.4, 66.3), 99.9%
158 (96.2, 100) respectively. Vaccine efficacy of 50%, 70%, and 90% against symptomatic infection
159 was achieved at anti-spike IgG levels of 32 (95% CrI: 0, 57), 78 (51, 139), 182 (105, 507) BAU/mL
160 respectively (Supplementary Table 7). Against any COVID-19 infection higher antibody levels
161 were required for the same efficacy, 84 (95% CrI: 59, 125), 156 (109, 285), 311 (194, 662) BAU/mL
162 respectively.

163 **Waning vaccine efficacy**

164 As the antibody levels decayed over time, the vaccine efficacy waned. Fig. 3 shows the mean VE
165 over time since the second dose, averaged over all individuals in the study. We report efficacy 7
166 days after the planned study visits. The efficacy at day 35 after the second dose was estimated
167 to be 88.1% (95% CrI: 77.2, 93.6) against symptomatic infection and 76.0% (64.3, 83.7) against
168 all COVID-19 infection. The efficacy waned to 77.7% (68.5, 84.1) and 60.8% (51.4, 68.4) at day
169 97 and 60.4% (44.6, 71.0) and 39.6% (26.1, 50.2) at day 189 against symptomatic infection and
170 all COVID-19 infection respectively.

171 Levels of protection varied based on individual antibody responses. At day 28, the predicted 25%,
172 50% and 75% antibody quantiles were 124 (95% CrI: 117, 130), 217 (208, 227), 378 (359, 398)
173 BAU/mL respectively (Supplementary Fig. 9). The corresponding VE quantiles at day 35 against
174 symptomatic infection were 81.4% (95% CrI: 68, 93.7), 93.1% (76.6, 99.4), 98.8% (85.2, 100), and
175 against any COVID-19 infection were 62.1% (49.7, 75.1), 80.5% (63.1, 92.7), 93.8% (77.1, 99.1)
176 (Supplementary Fig. 8). At day 182, the respective antibody quantiles were 26 (23, 29), 49
177 (45, 54), 91 (82, 102) BAU/mL, and corresponding VE quantiles were 46.3% (16.1, 65.3), 58.8%
178 (44.9, 69.5), 73.9% (62.6, 85.6) against symptomatic infection, and 23.6% (-0.8, 41.5), 35.5%
179 (21.6, 47.1), 52.5% (42.1, 62.3) against any COVID-19 infection.




Figure 2: Vaccine efficacy as a function of anti-spike IgG levels. VE (%) plotted against anti-spike IgG antibody levels (BAU/mL) on a log scale. The red and blue curves and shaded regions show the posterior median and associated 95% credible intervals for VE against primary symptomatic COVID-19 infection, and against all NAAT+ positive tests respectively. The vertical dotted line shows the lower limit of quantification (LLOQ), 0.21 BAU/mL. The blue histogram shows the distribution of the predicted anti-spike IgG antibody levels in the study at 28 days since the second dose, and the green histogram at 182 days post second dose. The two histograms overlap. The heights of the histograms are not to scale.




Figure 3: Vaccine efficacy as a function of time since second dose vaccination. The red curve and shaded region shows the posterior median and associated 95% credible interval for VE against symptomatic COVID-19 infection, and the blue curve and shaded region shows the posterior median and 95% credible interval for VE against all positive COVID-19 tests.

180 Covariate effects on antibody levels and vaccine efficacy waning

181 We report the estimated effects of different covariates on initial antibody response, subsequent
182 antibody decay, and vaccine efficacy over time. Our model predicts a large decrease in antibody
183 levels for those with shorter intervals between the first and second dose (Fig. 4, Supplementary
184 Table 5). Compared with participants with dose intervals of ≥ 12 weeks, participants with dose
185 intervals of 9-11 weeks, 6-8 weeks and < 6 weeks have predicted anti-spike IgG antibody levels
186 83% (95% CrI: 74, 93), 70% (61, 81), 51% (43, 61) as high respectively, at 28 days after the
187 second dose. We also predict a larger antibody response due to receiving a low dose as the
188 first dose compared with a standard dose, although 95% credible intervals contain a null effect.
189 We predict lower antibody responses at 28 days after the second dose in older age groups, and
190 among healthcare workers. Higher antibody responses are predicted in females than males, and
191 in non-white participants. Shorter half-lives of antibody levels are predicted for females, and
192 individuals with a BMI ≥ 30 (Fig. 4, Supplementary Table 5).

193 To consider covariate effects on VE, we compare with reference values of age 18-55 years, female,
194 white ethnicity, no comorbidities, BMI < 30 kg/m², ≥ 12 week interval between first and second
195 dose, non-HCW (non-healthcare worker), and receiving a standard dose as their first dose. We
196 then vary each of these covariates and plot VE for each covariate combination against symp-
197 tomatic infection in Fig. 5 and against all COVID-19 infection in Supplementary Fig. 10. We see
198 that shorter intervals between first and second dose predict a lower VE throughout the study.
199 VE against symptomatic infection at day 35, 97 and 189 was 93.1% (CrI: 81.6, 97.6), 85.0%
200 (72.1, 92.1) and 68.7% (53.2, 77.4) respectively for a reference individual (with ≥ 12 week inter-
201 val), compared with 83.2% (71.6, 91.0), 71.7% (58.2, 80.4) and 55.0% (27.0, 69.2) respectively
202 for an individual with < 6 week interval. We also observe a lower efficacy after around 90 days
203 in individuals aged 70 years or older compared with the 18-55 and 56-69 years age groups. VE
204 for an individual aged 70 years or older at day 35, 97 and 189 was 90.7% (78.8, 96.4), 79.2%
205 (67.5, 88.2) and 59.9% (35.2, 72.7) respectively, compared with a reference individual above.




Figure 4: Covariate effects on anti-spike IgG antibody levels. The multiplicative effects on (a) day 28 anti-spike IgG antibody levels and (b) half-life of anti-spike IgG antibody decay for different covariates. The effects are plotted on a log scale. These results are also given in Supplementary Table 5.




Figure 5: Vaccine efficacy against symptomatic COVID-19 infection plotted against time since vaccination for different covariate combinations. The black lines represent an individual with reference covariates: age 18-55, female sex, white ethnicity, no comorbidities, BMI < 30 kg/m², ≥ 12 week interval between first and second dose, non-HCW (healthcare worker), and receiving a standard dose as their first dose. All other coloured lines represent an individual with one of the above covariates changed from these reference values. The solid lines show posterior medians and dashed lines 95% credible intervals. "HCW < 1 COVID" refers to a healthcare worker facing <1 COVID-19 patient per day, "HCW ≥ 1 COVID" refers to a healthcare worker facing ≥ 1 COVID-19 patient per day.

Table 1: Comparison of methods and results with previous correlates of protection studies

Paper	Antibody type	Vaccine	Doses	Dominant variant	Timing of antibody effect on risk [†]	Accounts for measurement error	Accounts for antibody waning between measurement and exposure	Accounts for individual variation in slopes	Randomised vaccine /control assignment	Unvaccinated baseline comparator	Location of result in paper	Endpoint	Antibody level (BAU/mL unless otherwise stated)	Vaccine efficacy (%)	Our result
Feng et al. (2021) [1]	Spike nAb* others*	ChAdOx1 [†]	Two doses	Pre-Delta (Alpha B.1.1.7 and B.1.177)	Peak (~28 (14-42) days post second dose)	x	x	x	✓	✓	Table 2 (Fig. 4a)	Symptomatic Asymptomatic*	29 (NC, 83) 54 (NC, 143) 113 (NC, 245) 264 (108, 806) 899 (369, NC) [‡]	50% 60% 70% 80% 90%	32 (0, 57) 32 (0, 82) 78 (51, 139) 117 (76, 266) 182 (105, 307) BAU/mL
Benkeser et al. (2023) [2]	Spike nAb* others*	ChAdOx1 [†]	Two doses	Pre-Delta (B.1.2)	Peak (~28 days post second dose)	x	x	x	✓	✓	In text and Fig. 5a	Symptomatic	21 100 1000	21.1% (-361, 79.3) 62.9% (-55.0, 85.7) 88.1% (52.0, 97.0)	43.3% (6.6, 64.6) 76.1% (64.4, 88.7) 100% (97.3, 100) VE (%)
Wei et al. (2022) [9]	Spike	ChAdOx1 [†] BNT162b2*	Two doses	Delta (B.1.617.2)	Exposure (21-59 days prior to infection)	x	x	x	x	✓	Fig. 4c	Symptomatic Any infection* Ct<30*	25 100 400	55% (40, 65) 68% (59, 75) 82% (74, 88)	45.8% (14.5, 65.2) 76.1% (64.4, 88.7) 99.0% (86.2, 100) VE (%)
Wei et al. (2023) [10]	Spike	ChAdOx1 [†] BNT162b2*	Two doses plus booster or infection	Omicron BA.4/5 (B.1.1.529)	Exposure (21-59 days prior to infection)	x	x	x	x	Compared with vaccine non-responders [¶]	Supp. Fig. 1 and Fig. 1a	Any infection Symptomatic* Ct<30*	920 (766, 1092) 1740 (1502, 2331) 3680 (2831, 4500)	50% 70% 80%	32 (0, 57) 78 (51, 139) 117 (76, 266) BAU/mL
Follmann et al. (2023) [11]	nAb	mRNA-1273	Two doses	Pre-Delta period	Exposure (7 days prior to infection)	x	✓	x	✓	✓	In text and Fig. 2	Symptomatic	100 IU50/mL 1000 IU50/mL (Neutralising antibody)	93% (91, 95) 97% (95, 98)	No comparison possible
Our analysis	Spike	ChAdOx1 [†]	Two doses	Pre-Delta (Alpha B.1.1.7 and B.1.177)	Exposure (7 days prior to infection)	✓	✓	✓	✓	✓	In text and Fig. 2	Symptomatic Any infection*	10 100 1000	36% (-21, 63) 76% (64, 89) 100% (97, 100)	

We include studies of the ChAdOx1 nCoV-19 vaccine, as well as studies which relate antibody levels at the time of exposure to risk of infection, for comparison. Results are given with 95% confidence intervals or credible intervals, depending on the paper. Some results show the antibody level required for a certain vaccine efficacy, others show the vaccine efficacy associated with a certain antibody response. *We do not report these results here, see the original paper. [†]ChAdOx1 refers to the ChAdOx1 nCoV-19 vaccine in this table. [‡]Some studies relate antibody levels at the peak response after vaccination to risk of infection, others relate antibody levels at exposure to infection. This column denotes the time at which the antibody measurement was taken which relates to risk of infection, or the time at which the modelled antibody level relates to risk of infection (for analyses which use an antibody measurement directly or model antibody levels over time respectively). [§]NC = not computed (beyond data range). [¶]Wei et al. (2023) define vaccine non-responders to be vaccinated individuals with a recent anti-spike IgG measurement of 16 BAU/mL.

206 Discussion

207 We estimated correlates of protection, vaccine efficacy waning and antibody waning after two
208 doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine, against any COVID-19 infection and symp-
209 tomatic COVID-19 infection. We fit a two-stage joint model using multiple imputation [31] which
210 accounts for antibody waning and measurement error, allowing the risk of infection to depend
211 on the estimated anti-spike IgG level at exposure. We found antibody levels are predictive of
212 vaccine efficacy, which wanes over time, but continues to protect against the Alpha variant 209
213 days after the second dose. We estimated mean VE against symptomatic infection to be 88.1%
214 (95% CrI: 77.2, 93.6) at day 35, waning to 60.4% (44.6, 71.0) at day 189 (Results). There was
215 noticeable variation in VE between individuals, depending on the strength of their antibody
216 response. We reported that a longer interval between the first and second vaccine dose gives
217 improved protection, adding to existing evidence [34, 35, 9]. VE after 3 months since second
218 dose vaccination was also lower in individuals aged 70 years or older than in younger age groups.
219 We estimated “exposure-proximal” correlates of protection by relating modelled antibody levels
220 at the time of exposure to the risk of COVID-19 infection. This approach more closely matches
221 the biological mechanism than relating peak antibody levels to risk of infection. Table 1 com-
222 pares our methods and results with previous studies of COVID-19 correlates of protection. As
223 outlined in the introduction, previous analyses have demonstrated both binding and neutralising
224 antibodies measured at a fixed time after vaccination are associated with VE against COVID-19,
225 including a study analysing data from the same COV002 trial [1], an analysis of data from a
226 different trial of the ChAdOx1 nCoV-19 vaccine [2], as well as analyses of trials of other vac-
227 cines [3, 4, 5], and booster doses [6, 7]. These studies compared peak antibody levels and risk
228 of infection, and generally report wide confidence intervals due to a lack of power. They did
229 not account for antibody waning between the time of measurement and exposure, which may
230 introduce a bias[8]. Other studies have estimated correlates of protection by relating antibody
231 levels at the time of exposure to the risk of infection, by using a recent antibody measurement
232 [9, 10], or a model to predict antibody decay over time [11]. However the studies using a recent
233 antibody measurement (Wei et al. 2022, 2023) used observational data from a cohort study, and
234 did not account for antibody waning between measurement and exposure, which may introduce
235 bias [9, 10]. The study modelling antibody levels over time (Follmann et al. 2023) assumed the
236 rate of antibody decay to be the same for all individuals in the study, which may introduce
237 bias if it decay rates vary [11]. All the above studies only used one antibody measurement per
238 individual, meaning they are unable to account for measurement error in the antibody levels,
239 which may bias the analysis [12]. None of these prior studies relate protection against COVID-19
240 infection to antibody levels at the time of exposure while also accounting for measurement error
241 or variation between individual rates of antibody level decay.

242 We used a two-stage joint model to relate modelled antibody levels at the time of exposure
243 to the risk of infection. Joint models have been shown to reduce bias and improve power in
244 estimating the relationship between longitudinal outcomes (e.g. antibody levels) and the time

245 until an event (e.g. infection) [36, 25], as well as in estimating the trajectory of the longitu-
246 dinal variable (antibody levels) [36]. Moreno-Bentacur et al. (2018) previously found using a
247 multiple imputation-based joint model reduced bias, when compared with using the longitudi-
248 nal observations directly to predict risk [25]. We include multiple antibody measurements per
249 individual where available, allowing us to account for measurement error and variation between
250 individual rates of decay. We further account for the informative censoring of antibody data
251 after infection. We are not aware of any previous work applying joint modelling to understand
252 how vaccine-induced immune responses relate to risk of infection for COVID-19 or any other
253 infectious disease.

254 We observe higher vaccine efficacy with much lower uncertainty at the same level of antibody,
255 compared with the studies relating peak antibody levels to risk of infection [1, 2] (Table 1). The
256 lower efficacy these studies report is likely due to antibody waning between the measurement
257 and exposure, meaning higher initial antibodies would be required to give the same protection
258 at exposure. These models also do not account for measurement error, which introduces noise to
259 the data, likely causing the observed protective effect to be diluted [12]. Our results are broadly
260 similar to those of Wei et al. (2022) who relate antibody levels at the time of exposure to risk of
261 infection [9] (Table 1). Much higher antibody levels are required for similar levels of protection
262 against the Omicron variant [10]. We are unable to compare with the results of Follmann et al.
263 (2023), as their paper uses neutralising antibodies, whereas we use anti-spike IgG [11].

264 We estimated the peak antibody response at 28 days after ChAdOx1 nCoV-19 vaccination, the
265 subsequent rate of decay, and associated covariate effects. Table 2 compares our methods and
266 results with previous studies. Wei et al. (2022) previously used a similar approach applied to non-
267 randomised cohort data [9]. Their model does not account for the aforementioned informative
268 censoring of antibody measurements, which may lead to bias [36]. This is because individuals
269 with lower antibody levels will be more likely to test positive for COVID-19, after which anti-
270 body measurements will be excluded from analysis. Thus individuals with lower antibody levels
271 are less likely to have antibody measurements available, introducing informative missing data,
272 which should be accounted for. However, as cases are rare in the population, this bias may be
273 small. We estimated higher peak anti-spike IgG levels than Wei et al. study [9] (Table 2). This
274 may be partly due to differences in the populations enrolled in the two studies. Our estimated
275 half-life of antibody decay was broadly similar to previous results (Table 2). We observed indi-
276 viduals with longer dose intervals had higher peak antibody levels (Fig. 4, Supplementary Table
277 5), as previous studies have reported [35, 34, 9]. We also observed higher peak antibody levels
278 in younger individuals (18-55 vs ≥ 70), non-healthcare workers and non-white participants. The
279 higher peak in non-white participants was also observed by Wei et al. (2022) [9], however there is
280 no consensus on the effect of age and healthcare work on antibody levels (Table 2). We reported
281 slower antibody decay in participants with a BMI < 30 kg/m² (Fig. 4, Supplementary Table 5),
282 and detected slightly slower antibody decay in males, however this does not translate to a no-
283 ticeable difference in VE waning (Fig. 5, Supplementary Fig. 10). Neither of these differences

284 have been reported elsewhere and it is unclear if they represent true effects. We did not detect
285 the other effects on peak antibody observed by Wei et al. (2022) [9].
286 We reported predicted vaccine efficacy over time since second dose from our model, calculated
287 from randomised controlled trial data. One previous analysis considered waning after a first
288 dose of ChAdOx1 nCoV-19 [34], however the analysis was underpowered. Apart from this, we
289 are not aware of any studies of ChAdOx1 nCoV-19 vaccine efficacy waning evaluated on ran-
290 domised data. Table 3 and Supplementary Table 8 compare our methods and results to previous
291 studies of waning vaccine efficacy, with a focus on studies of the ChAdOx1 nCoV-19 vaccine.
292 These studies all use non-randomised observational data, including test-negative design studies
293 [13, 14, 15, 18], and cohort studies [37, 15, 16, 17]. The test-negative design may introduce bias
294 due to unmeasured differences in health-seeking behaviour between the vaccinated and unvac-
295 cinated arms, likely reducing the observed VE [20, 21]. Results may also not carry over to the
296 wider population, as those included in the study will likely test more frequently. Cohort studies
297 are similarly vulnerable to biases due to unmeasured confounding causing differences in risk of
298 infection between the unvaccinated and vaccinated populations. Such biases may increase over
299 time, as the unvaccinated group are increasingly unvaccinated by choice, which may correlate
300 with fewer health-seeking behaviours. Further, accumulation of more undetected infections in
301 the unvaccinated arm may lead to VE waning to appear greater, due to the so-called depletion of
302 susceptibles bias [38]. This bias may occur in randomised or observational data. Asymptomatic
303 swabbing may negate this bias by increasing the proportion of infections which are detected.
304 Rates of asymptomatic swabbing were high in our study [39], with around 75% of participants
305 returning an asymptomatic test on a given week. Rates of asymptomatic swabbing were likely
306 much lower in the other studies, where participants were not encouraged to swab weekly.
307 Our analysis has some advantages over these methods. The data comes from a randomised
308 single-blinded controlled trial, avoiding the potential biases of an observational cohort study
309 and a test-negative case-control study. We model antibody waning and vaccine efficacy waning
310 jointly over time, which may improve the efficiency of our estimates [22]. Further, the length
311 of follow-up in our study after second dose was relatively long at over 29 weeks. However, the
312 sample size of our data is much smaller than most of these studies, hence we report wider CrIs.
313 Table 3 and Supplementary Table 8 compare our methods and results to previous studies of vac-
314 cine efficacy waning against different variants. Results from previous studies varied by variant,
315 with lower efficacy generally predicted against Delta than Alpha, and lower still against Omicron
316 (Table 3, Supplementary Table 8). Our study reports efficacy over time since second dose against
317 the Alpha variant. Note the predicted vaccine efficacy for a reference individual reported in Table
318 3 and Figure 5 was slightly higher than the mean vaccine efficacy across all individuals (Fig. 3),
319 primarily because the mean vaccine efficacy averaged over all individuals including those who
320 had a shorter dose interval than 12 weeks. We predicted a slightly higher vaccine efficacy against
321 symptomatic infection with the Alpha variant after two doses of ChAdOx1 nCoV-19 (Table 3,
322 Fig. 5) than Andrews et al. (2022a) in all age groups, although confidence intervals overlapped

323 [13]. Other studies were conducted at least partly in periods where the Delta or Omicron variants
324 were dominant, and generally reported lower vaccine efficacy. Reported efficacy varied notice-
325 ably between studies (Table 3, Supplementary Table 8). Differences in results between studies
326 may be due to different proportions of circulating variants, rates of asymptomatic swabbing, and
327 characteristics of the study populations, as well as the depletion of susceptibles bias, and previ-
328 ously mentioned biases due to unmeasured confounding. Our results against the Alpha variant,
329 calculated on data from a randomised single-blinded study, are free from bias due to unmeasured
330 confounding.

331 Our data was collected in a period when the Alpha variant was dominant, and considered in-
332 dividuals without prior infection who received two doses of vaccine. In contrast, the Omicron
333 variant is currently dominant, and many individuals have received three or more doses of vaccine
334 and been previously infected. Therefore our results may not be directly applicable to current
335 and future situation. To aid with this, we performed a supplementary analysis extrapolating our
336 results to examine what the efficacy over time since second dose might have been, in the hypo-
337 theoretical scenario where the study was conducted in the Omicron BA.4/5 period. The analysis
338 suggests a weak initial protection against Omicron BA.4/5, waning to negligible protection after
339 6 months. See the Supplementary Information (Sections 1.4.6, 2.1, 3, Supplementary Fig. 11)
340 for further details.

341 We further reported covariate effects on vaccine efficacy, although this analysis lacked power. We
342 observed lower vaccine efficacy for individuals with shorter intervals between the second dose;
343 results from previous studies have provided varying degrees of evidence for this [40, 14, 13].
344 We reported lower VE in older individuals after around 3 months since the second dose (Fig.
345 5, Supplementary Fig. 10), with overlapping credible intervals. Faster waning [13] and lower
346 VE [37, 16] have been previously observed in older individuals. However, these effects were not
347 observed in all groups in the Andrews et al. study, with non-significant effects in the opposite
348 direction observed in some groups [13], and the Nordström et al. age estimates were unadjusted
349 and likely confounded due to different vaccines being given to different age groups [37]. Another
350 observational study observed higher efficacy in individuals aged 80+ years than 50-79, while
351 suggesting this could be confounded by clinical risk [40]. Hence further research on the effect
352 of age on vaccine efficacy is necessary. We did not observe a difference in vaccine efficacy for
353 individuals with comorbidities, although some prior studies suggest a lower VE in clinically vul-
354 nerable individuals [16, 37, 13].

355

Table 2: Comparison of methods and results with previous studies of antibody level waning

Paper	Vaccine	Randomised vaccine /control assignment	Account for informative censoring at infection	Random individual slopes	Antibody type	Time of reported peak antibodies	Two-dose /booster /prior infection	Peak anti-spike IgG antibody level (BAU/mL)	Antibody half-life (days)	Covariates related to increased peak antibody levels	Covariates related to slower antibody decay
Wei et al. (2022) [9]	ChAdOx1 nCoV-19 BNT162b2*	x	x	✓	Anti-spike IgG	21 days post second dose	Two-dose	184 (183, 185)	Mean 79 (78, 80)	Older age Female Non-white No LTHC Prior infection Healthcare worker Longer dose interval More deprivation	Younger age White No LTHC
Aldridge et al. (2022) [41]	ChAdOx1 nCoV-19 BNT162b2*	x	x	x	Anti-spike IgG	28 days post second dose	Two-dose	-	105.9	None	None
Wei et al. (2023) [10]	ChAdOx1 nCoV-19 BNT162b2	x	x	✓	Anti-spike IgG	21 days post second dose	Booster: BNT162b2 mRNA-1273 Infection	-	78 (72, 86) 63 (61, 66) 96 (80, 119)	Younger age Longer dose interval	Not reported
Our analysis	ChAdOx1 nCoV-19	✓	✓	✓	Anti-spike IgG	28 days post second dose	Two-dose	217 (208, 227)	Median 74 (69, 79)	Younger age (18-69) Non-white Longer dose interval Not HCW	Male BMI <30 kg/m ²

We include studies of two doses of the ChAdOx1 nCoV-19 vaccine, and studies after a subsequent booster vaccine, focussing on anti-spike IgG antibody waning. Results are given with 95% confidence intervals or 95% credible intervals, depending on the paper. We report covariate effects where the null effect is not included in the 95% interval. HCW = healthcare worker, LTHC = long-term health condition. *We do not report these results here, see the original paper.

Table 3: Comparison of methods and results with previous vaccine efficacy waning studies, against the Alpha and Delta variants

Paper	Primary course vaccine	Dominant variant	Two-dose /booster /prior infection	Study design	Randomised vaccine /control assignment	Baseline comparator	Outcome	Location of result in paper	Group	Weeks since dose	Vaccine efficacy (%)
Our analysis [†]	ChAdOx1 nCoV-19	Alpha	Two dose	Randomised Controlled Trial	✓	Unvaccinated	Symptomatic	Fig. 5	Age 18-55	5 10 20 26	93.1 (81.6, 97.6) 89.0 (76.6, 95.1) 77.7 (64.5, 85.7) 70.0 (55.0, 78.5)
									Age 56-69	5 10 20 26	91.8 (80.0, 97.0) 88.1 (76.1, 94.7) 78.5 (66.3, 88.0) 72.2 (57.2, 83.1)
							Any infection	Supp. Fig. 10	Age 70+	5 10 20 26	90.7 (78.8, 96.4) 84.7 (73.0, 92.4) 69.9 (54.5, 80.4) 61.3 (38.1, 73.6)
									Age 18-55	5 10 20 26	84.3 (70.6, 91.8) 77.2 (62.7, 86.1) 60.5 (46.1, 70.1) 50.6 (34.8, 60.1)
Andrews et al. (2022a) [13]	ChAdOx1 nCoV-19 BNT162b2*	Alpha Delta*	Two dose	Test-negative	x	Unvaccinated	Symptomatic	Table S11	Age 16+ Age 40-64 Age 65+	2-9 10+ 2-9 2-9	82.4 (79.6, 84.7) 76.2 (49.8, 88.7) 81.7 (76.0, 86.1) 88.2 (82.2, 92.1)
Nordström et al. (2022) [37]	ChAdOx1 nCoV-19 BNT162b2* mRNA-1273*	Alpha and Delta (Combined)	Two dose	Cohort	x	Unvaccinated	Any infection	Table 2	Alpha, Delta and all ages combined	2-4 4-9 9-17 ≥ 17	68 (58, 70) 49 (28, 64) 41 (29, 51) -19 (-98, 28)
Skowronski et al. (2022) [14]	ChAdOx1 nCoV-19 BNT162b2* mRNA-1273* Mixed schedules*	Alpha Delta	Two dose	Test-negative	x	Unvaccinated	Any infection Hospitalisation*	Supp. Table 12	Quebec (Alpha and Delta) British Columbia (Delta)	4-7 8-11 20-23 24-27 4-7 8-11 20-23 24-27	90 (84, 94) 85 (81, 88) 70 (64, 75) 56 (43, 65) 77 (71, 82) 76 (73, 79) 74 (70, 78) 67 (48, 80)

We include studies of two doses of the ChAdOx1 nCoV-19 vaccine, prior to the Omicron variant. Results are given with 95% confidence intervals or 95% credible intervals, depending on the paper. Results are presented for different age groups, where appropriate. *We do not report these results here, see the original paper. [†]We report here the predicted vaccine efficacy for a reference individual in the given age group, with covariates: female, white, no comorbidities, BMI<30 kg/m², ≥12 week interval, not a healthcare worker, standard dose.

356 Our study has several limitations. Our results may not be directly applicable to current and
357 future populations, for four reasons. Firstly dominant variants have changed from B.1.177 and
358 Alpha (B.1.1.7) variants when our data was collected, to the Omicron variant today. Secondly
359 individuals in the study were SARS-CoV-2 naïve, results will likely differ in individuals with
360 prior infection [10]. Thirdly individuals in the study received two doses of ChAdOx1 nCoV-19,
361 whereas three or more doses of different vaccines have been given in many populations.
362 Fourthly the study population differs from the general population, being predominantly white,
363 18-55 years old and including mostly healthcare workers. For these reasons our results are
364 unlikely to transfer directly to the general population today, although qualitative aspects of our
365 results, and our methods, remain relevant. We further only consider the effect of anti-spike IgG
366 binding antibodies, and do not measure neutralising antibodies or cellular immune responses.
367 It may be that the protection conferred by other immune responses depends on the antibody
368 level, or changes with time, whereas we assumed a constant effect. We did not consider the
369 effect on risk of hospitalisation, severe disease and death due to insufficient data. Fewer
370 antibody observations were available at the later timepoints (PB90 and PB182 study visits),
371 causing greater uncertainty in our estimates at later times. We assumed a 7 day gap from
372 exposure to reported infection; deviation from this assumption may introduce a small bias to
373 our analysis. We did not account for the change in dominant variant from B.1.177 to B.1.1.7
374 (Alpha) during the study, however we expect the impact of this on VE to be negligible [42].
375 The dose of virus that individuals were exposed to may have varied throughout the study, as
376 social distancing policies changed. Further, viral load is likely to have varied between
377 individuals depending on previous exposure to COVID-19, and the variant to which they were
378 exposed. We have not accounted for differences in viral load or dose of virus in this analysis.
379 In summary, we report correlates of protection against any COVID-19 infection and
380 symptomatic infection from a randomised COVID-19 vaccine study, using binding antibody
381 responses at the time of exposure. We further report vaccine efficacy waning over time,
382 antibody waning over time, and associated covariate effects. We use a joint model which
383 accounts for antibody measurement error, the waning of antibody levels over time, and
384 censoring of antibody observations at COVID-19 infection. This may reduce bias and increase
385 power in the analysis compared with previous approaches.

386 **Methods**

387 **Study description**

388 We analysed data from COV002 (registration NCT04400838), a phase 2/3 randomized
389 single-blind vaccine efficacy (VE) trial conducted across 19 sites in the United Kingdom. A full
390 description of the trial including immunogenicity, efficacy, and safety data, and the protocol has
391 been previously published [32, 33, 34, 42]. An analysis of immune correlates of protection,
392 relating antibody measurements 28 days after the second dose with protection against

393 infection, was previously published [1].

394 This study was approved in the United Kingdom by the Medicines and Healthcare products
395 Regulatory Agency (MHRA), reference 21584/0428/001–0001, and the South-Central Berkshire
396 Research Ethics Committee, reference 20/SC/0179. All participants provided informed consent.
397 Participants in the study were randomized to receive ChAdOx1 nCoV-19 (AZD1222) or a
398 MenACWY control vaccine. The randomization ratio (ChAdOx1 nCoV-19:MenACWY)
399 differed by study cohort, and was either 1:1, 5:1, or 3:1. Open label groups are not included in
400 this analysis.

401 **Study endpoints and outcomes**

402 Participants were sent weekly reminders to contact their study site if they experienced any of
403 the primary symptoms of COVID-19 (fever ≥ 37.8 °C; cough; shortness of breath; anosmia or
404 ageusia) and were then assessed in clinic, by taking a nose and throat swab by a nucleic acid
405 amplification test (NAAT). In addition, participants were asked to complete a nose and throat
406 swab at home each week.

407 The outcomes for this analysis were (1) primary symptomatic COVID-19 infection, that is a
408 nucleic acid amplification test positive (NAAT+) swab with at least one qualifying symptom,
409 (2) any COVID-19 infection, that is any NAAT+ swab.

410 All endpoints were evaluated by a blinded independent clinical review committee. The date of
411 onset of infection was determined by the committee, as the earliest time at which there was
412 evidence of infection. Evidence included NAAT+ swabs and self-reported symptoms based on
413 telephone contact and study visits.

414 **Antibody measurements**

415 A proportion of serum samples from vaccine recipients at the PB28, PB90 and PB182 study
416 visits were tested for anti-SARS-CoV-2 Spike IgG in a single laboratory assay. For PB28
417 samples, all NAAT+ cases were tested if sample volume allowed, and a proportion of non-cases
418 were tested. Samples were tested blinded to case status. The data from noncases was obtained
419 first, and consisted mainly of the samples processed for the initial application for emergency
420 use, which needed 15% of samples included in the efficacy cohort to be processed on validated
421 assays. Subsequent to this PB28 samples from NAAT+ cases were sent for testing as they
422 occurred, if not already including the 15%. A proportion of those participants with samples
423 tested at PB28 were additionally tested at either PB90 only, or PB90 and PB182. We assume
424 the samples to be missing at random, i.e. the missingness depended only on factors observed in
425 the study. To account for the missing data, factors associated with sample availability were
426 included as covariates in the model for antibody decay (see ‘Antibody decay model’ below).

427 Anti-SARS-CoV-2 Spike IgG was measured by a multiplex immunoassay on the MSD platform
428 at PPD Laboratories. The assay sequences were based on the ancestral sequences from Wuhan,

429 China. Assay validation included precision and ruggedness, dilutional linearity, selectivity, and
430 relative accuracy for each SARS-CoV-2 antigens. Post-validation studies for stability and for
431 conversion to the WHO standard, as well as the establishment of a cut-point, were performed.
432 The lower limit of quantification (LLOQ) for anti-spike IgG was 33 AU/mL (0.21 BAU/mL).
433 We excluded 8 anti-spike IgG results as outliers - three results at PB28 and four at PB90 whose
434 anti-spike IgG levels were especially low, and one results at PB90 whose levels were especially
435 high (Supplementary Table 3, Supplementary Fig. 2). The individuals from whom these
436 samples were taken, and any other antibody measurements are included in the analysis - only
437 the outlying antibody measurements are excluded. Outliers were excluded as they may bias the
438 results [43].

439 The assay was analysed in its original scale. Results were then converted to the WHO
440 international standard units, binding antibody units per mL (BAU/mL), by multiplying by a
441 conversion factor supplied by the laboratory. The anti-spike IgG conversion factor from
442 arbitrary units per mL (AU/mL) to WHO standard binding antibody units per mL (BAU/mL)
443 was 0.00645 (95% confidence interval (CI): 0.00594, 0.00701). We did not apply the CI, as it
444 represents the uncertainty due to measurement error in the assay, and our antibody model
445 already accounts for this.

446 Study design

447 We included a subset of participants in the COV002 trial in our study, who met the following
448 eligibility criteria: received two doses of ChAdOx1 nCoV-19 or MenACWY control vaccine,
449 baseline seronegative to the SARS-CoV-2 N protein at first vaccination, and followed up to at
450 least day 21 post second vaccination with no evidence of prior infection. Vaccinated
451 participants received a first and second dose: either two standard doses, low dose followed by
452 standard dose, or two low doses. Nine participants who received mixed schedules in error (one
453 dose of ChAdOx1 nCoV-19 and one dose of MenACWY control) were excluded from the
454 analysis (Supplementary Fig. 1). One control individual had missing BMI, we imputed this
455 with the mean value in the study.

456 Participants were considered at-risk of the study event from day 21 post second dose. The
457 at-risk period ended at the first of: the onset of COVID-19 infection, withdrawal, unblinding,
458 or the analysis cut-off date 30 June 2021. Antibody levels were assumed to relate to risk of
459 infection 7 days later, to account for the gap between first being exposed to COVID-19 until a
460 case is reported in the trial. Thus antibody measurements are excluded if taken prior to 14
461 days after the second dose, after the end of the at-risk period, or less than 7 days before the
462 end of the at-risk period.

463 Participants who tested NAAT+ during the at-risk period were defined as cases, those who also
464 had at least one qualifying symptom were defined as symptomatic cases, while those who did
465 not return a positive test during the at-risk period were defined as non-cases.

466 Statistical Analysis

467 We modelled antibody decay and the risk of COVID-19 infection in a two-stage joint model for
468 longitudinal and survival data. Joint models are a popular method to consider the relationship
469 between a longitudinal biomarker and the risk of a health outcome, especially in studies of
470 disease progression such as HIV and cancer trials [8]. We employed a two-stage multiple
471 imputation approach to overcome convergence issues that arose when attempting to fit a full
472 joint model. A mathematical formulation of the model, and an explanation of how the
473 two-stage method approximates a Bayesian joint model, are given in the Supplementary
474 Methods.

475 **Antibody decay model** In the first stage, we fit a log-linear Bayesian mixed effects model
476 to the antibody decay after vaccination for ChAdOx1 nCoV-19 recipients (see Supplementary
477 Methods). The Bayesian approach easily accounts for the complex structure of the data and
478 the model, including missing antibody observations for some individuals, and unknown true
479 antibody levels which change over time. We first standardised the data; after running the
480 model we transformed the parameters back to the scale of the original dataset. The log
481 antibody observations were assumed to have t-distributed zero-mean random error, with 4
482 degrees of freedom and unknown scale (Supplementary Methods). The latent true log antibody
483 values were assumed to decay linearly from 14 days post second dose. The model included an
484 effect on both the peak antibody response (intercept) and rate of decay (slope) due to the
485 following covariates: age group (18-55 years, 56-69 years, 70+ years), sex (female, male),
486 ethnicity (white, non-white), comorbidity (none, comorbidity), BMI (<30 kg/m², ≥ 30), time
487 interval between first and second dose (≥ 12 weeks, 9-11 weeks, 6-8 weeks, <6 weeks),
488 healthcare worker (HCW) status (not a HCW, HCW facing <1 COVID-19 patient per day,
489 HCW facing ≥ 1 COVID-19 patient per day), initial dose (standard dose, low dose). The
490 probability of missing antibody data was observed to be related to whether an individual tested
491 positive and their follow-up time. To account for this, we also included covariate effects on the
492 intercept and slope due to: (i) returning a positive test during the study, (ii) being primary
493 symptomatic, and (iii) the Nelson–Aalen estimate of cumulative hazard for any COVID-19
494 infection in the vaccine group, as previously suggested [44]. We allowed a random intercept and
495 slope for each individual, as well as a correlation between the random effects. The slopes were
496 required to be negative, by applying the negative of the exponential function to the slope
497 parameter. This was done to avoid convergence issues in the risk of infection model due to
498 exponentially increasing antibody levels. The model predicts antibody trajectories for all
499 vaccinated individuals, with appropriate uncertainty. The model was fit using Hamiltonian
500 Monte Carlo in Stan [45]. Four chains were run, each of 20,000 iterations. The first 5,000
501 iterations were discarded as burn-in. Convergence was checked by ensuring the Rhat
502 convergence diagnostic (potential scale reduction factor) was less than 1.01 [46]. See the
503 Supplementary Information (Section 2.3) for the reported computation time.

504 **Risk of infection model** In the second stage, we fit a Cox model to the time until
505 COVID-19 onset (either primary symptomatic COVID-19 infection or any COVID-19
506 infection), using the output from the antibody model to predict the risk of infection. We
507 employed multiple imputation [31], which accounts for the uncertainty in the predicted
508 antibody levels in our estimation of the hazard (instantaneous risk) for infection (see
509 Supplementary Methods). A previously published multiple imputation-based joint model was
510 shown to reduce bias compared with single imputation “naïve” two-stage approaches [25]. We
511 first sampled 60,000 antibody trajectories from the first stage for each vaccinated individual,
512 from which we imputed the predicted antibody levels at each relevant time. For each sample,
513 we fit a Cox model for the time to infection. The baseline hazard varies with calendar time, to
514 account for the changing rates of COVID-19 in the population during the pandemic, and is
515 stratified by study site, to account for different rates across geographic regions. The hazard for
516 a given vaccinated individual i at time t then depends on the effect γ of their imputed antibody
517 levels $A_i(t - 7)$ at time $t - 7$, and a direct effect due to vaccination ζ , unrelated to antibody
518 levels. We further included covariate effects which may affect the risk of infection: age group
519 (18-55 years, 56-69 years, 70+ years), sex (female, male), ethnicity (white, non-white),
520 comorbidity (none, comorbidity), BMI (<30 kg/m², ≥ 30), healthcare worker (HCW) status
521 (not a HCW, HCW facing <1 COVID-19 patient per day, HCW facing ≥ 1 COVID-19 patient
522 per day). The hazard for a given control individual i at time t depends only on the baseline
523 hazard and covariates, we assume no antibody or vaccine effect for control individuals.
524 For each Cox model, we then drew from the asymptotic distribution of the maximum likelihood
525 estimators, to approximate a Bayesian posterior with diffuse improper priors [47]. We
526 combined this draw with the corresponding antibody model individual intercepts and slopes to
527 form a draw from the approximate joint distribution. Quantities of interest, such as vaccine
528 efficacy, can then be calculated from each draw. Posterior medians and 95% CrIs are calculated
529 based on quantiles of the posterior samples.

530 **Calculating vaccine efficacy** Vaccine efficacy (VE) at a given antibody level A is then
531 calculated as 1 minus the hazard ratio between a vaccinated individual with that level of
532 antibody, and a control individual with matching covariates.

$$\text{VE}(A) = 1 - \exp(\gamma A + \zeta) \quad (1)$$

533 with γ the antibody effect and ζ the direct effect due to vaccination. Antibody level at a given
534 VE is defined by the inverse of Eq (1). For individuals $i = 1, \dots, n$ in the vaccine arm, let
535 $A_i(t - 7)$ be the latent antibody level at time $t - 7$. Then the mean VE at time t is the mean
536 VE among all the latent antibody levels of vaccinated individuals at time $t - 7$.

$$\text{VE}(t) = \frac{1}{n} \sum_{i=1}^n \text{VE}(A_i(t - 7)) = 1 - \frac{1}{n} \sum_{i=1}^n \exp(\gamma A_i(t - 7) + \zeta) \quad (2)$$

537 The q th quantile of VE at time t , $VE_q(t)$, is equal to the VE at the q th antibody quantile
538 $A_q(t)$, $VE_q(t) = 1 - \exp(\gamma A_q(t) + \zeta)$.

539 **Calculating covariate effects on vaccine efficacy** To calculate covariate effects on
540 vaccine efficacy, we predicted efficacy in new individuals with given covariate values. Note the
541 event indicators and Nelson–Aalen (N–A) estimate of cumulative hazard for a new individual
542 are unknown, as they depend on the infection outcome. We first built an imputation model to
543 sequentially impute the missing event indicators (infection, symptomatic) and N–A estimate,
544 which appear in the longitudinal antibody model, given the known covariates. We imputed
545 these missing covariates n times. For each set of imputed covariates, we drew from the
546 predictive distribution of antibody trajectories for a new individual with the given covariate
547 values, $A_j^{\text{pred}}(t), j = 1, \dots, n$. We then averaged these to calculate the mean risk of infection
548 given the known covariate values

$$VE(t) = \frac{1}{n} \sum_{j=1}^n VE(A_j^{\text{pred}}(t)) = 1 - \frac{1}{n} \sum_{j=1}^n \exp(\gamma A_j^{\text{pred}}(t) + \zeta) \quad (3)$$

549 **Software** Data analysis was performed in R version 4.3.1 [48], using RStudio [49], and
550 relying extensively on the following packages: survival [50], RStan [51], snowfall [52], ggplot2
551 [53]. RColorBrewer [54] and tidyr [55] were also used. Hamiltonian Monte Carlo algorithms
552 were run in Stan [45] via the R package RStan [51].

553 Data availability

554 Anonymized data will be made available via the Vivli platform <https://vivli.org/>. Source
555 data for the figures are provided with this paper where possible.

556 Code availability

557 The code used for the analysis is available at GitHub repository
558 <https://github.com/danphillipsstats/COVID-joint-model-CoP>.

559 References

- 560 [1] Feng, S. *et al.* Correlates of protection against symptomatic and asymptomatic
561 SARS-CoV-2 infection. *Nature Medicine* **27**, 2032–2040 (2021).
- 562 [2] Benkeser, D. *et al.* Immune correlates analysis of a phase 3 trial of the AZD1222
563 (ChAdOx1 nCoV-19) vaccine. *npj Vaccines* **8**, 36 (2023).

- 564 [3] Gilbert, P. B. *et al.* Immune correlates analysis of the mRNA-1273 COVID-19 vaccine
565 efficacy clinical trial. *Science* **375**, 43–50 (2022).
- 566 [4] Fong, Y. *et al.* Immune correlates analysis of the ENSEMBLE single Ad26. COV2. S dose
567 vaccine efficacy clinical trial. *Nature Microbiology* **7**, 1996–2010 (2022).
- 568 [5] Fong, Y. *et al.* Immune correlates analysis of the PREVENT-19 COVID-19 vaccine
569 efficacy clinical trial. *Nature Communications* **14**, 331 (2023).
- 570 [6] Hertz, T. *et al.* Correlates of protection for booster doses of the SARS-CoV-2 vaccine
571 BNT162b2. *Nature Communications* **14**, 4575 (2023).
- 572 [7] Zhang, B. *et al.* Omicron COVID-19 immune correlates analysis of a third dose of
573 mRNA-1273 in the COVE trial. *medRxiv* 2023–10 (2023).
- 574 [8] Ibrahim, J. G., Chu, H. & Chen, L. M. Basic concepts and methods for joint models of
575 longitudinal and survival data. *Journal of Clinical Oncology* **28**, 2796 (2010).
- 576 [9] Wei, J. *et al.* Antibody responses and correlates of protection in the general population
577 after two doses of the ChAdOx1 or BNT162b2 vaccines. *Nature Medicine* **28**, 1072–1082
578 (2022).
- 579 [10] Wei, J. *et al.* Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster
580 vaccination or breakthrough infection in the UK. *Nature Communications* **14**, 2799 (2023).
- 581 [11] Follmann, D. *et al.* Examining protective effects of SARS-CoV-2 neutralizing antibodies
582 after vaccination or monoclonal antibody administration. *Nature Communications* **14**,
583 3605 (2023).
- 584 [12] Hu, P., Tsiatis, A. A. & Davidian, M. Estimating the parameters in the Cox model when
585 covariate variables are measured with error. *Biometrics* 1407–1419 (1998).
- 586 [13] Andrews, N. *et al.* Duration of protection against mild and severe disease by Covid-19
587 vaccines. *New England Journal of Medicine* **386**, 340–350 (2022).
- 588 [14] Skowronski, D. M. *et al.* Two-dose severe acute respiratory syndrome coronavirus 2
589 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative
590 design studies from British Columbia and Quebec, Canada. *Clinical Infectious Diseases*
591 **75**, 1980–1992 (2022).
- 592 [15] Katikireddi, S. V. *et al.* Two-dose ChAdOx1 nCoV-19 vaccine protection against
593 COVID-19 hospital admissions and deaths over time: a retrospective, population-based
594 cohort study in Scotland and Brazil. *The Lancet* **399**, 25–35 (2022).
- 595 [16] Menni, C. *et al.* COVID-19 vaccine waning and effectiveness and side-effects of boosters: a
596 prospective community study from the ZOE COVID Study. *The Lancet Infectious*
597 *Diseases* **22**, 1002–1010 (2022).

- 598 [17] Horne, E. M. *et al.* Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines
599 over six months since second dose: OpenSAFELY cohort study using linked electronic
600 health records. *BMJ* **378** (2022).
- 601 [18] Andrews, N. *et al.* Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529)
602 variant. *New England Journal of Medicine* **386**, 1532–1546 (2022).
- 603 [19] Andrews, N. *et al.* Effectiveness of COVID-19 booster vaccines against COVID-19-related
604 symptoms, hospitalization and death in England. *Nature Medicine* **28**, 831–837 (2022).
- 605 [20] Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical basis of the
606 test-negative study design for assessment of influenza vaccine effectiveness. *American*
607 *Journal of Epidemiology* **184**, 345–353 (2016).
- 608 [21] Westreich, D. & Hudgens, M. G. Invited commentary: beware the test-negative design.
609 *American Journal of Epidemiology* **184**, 354–356 (2016).
- 610 [22] Fleming, T. R., Prentice, R. L., Pepe, M. S. & Glidden, D. Surrogate and auxiliary
611 endpoints in clinical trials, with potential applications in cancer and AIDS research.
612 *Statistics in Medicine* **13**, 955–968 (1994).
- 613 [23] Tsiatis, A. A. & Davidian, M. Joint modeling of longitudinal and time-to-event data: an
614 overview. *Statistica Sinica* 809–834 (2004).
- 615 [24] Gould, L. A. *et al.* Joint modeling of survival and longitudinal non-survival data: current
616 methods and issues. Report of the DIA Bayesian joint modeling working group. *Statistics*
617 *in Medicine* **34**, 2181–2195 (2015).
- 618 [25] Moreno-Betancur, M. *et al.* Survival analysis with time-dependent covariates subject to
619 missing data or measurement error: Multiple Imputation for Joint Modeling (MIJM).
620 *Biostatistics* **19**, 479–496 (2018).
- 621 [26] Néant, N. *et al.* Modeling SARS-CoV-2 viral kinetics and association with mortality in
622 hospitalized patients from the French COVID cohort. *Proceedings of the National*
623 *Academy of Sciences* **118**, e2017962118 (2021).
- 624 [27] Tong-Minh, K. *et al.* Joint modeling of repeated measurements of different biomarkers
625 predicts mortality in COVID-19 patients in the Intensive Care Unit. *Biomarker Insights*
626 **17**, 11772719221112370 (2022).
- 627 [28] Chen, X. *et al.* A predictive paradigm for COVID-19 prognosis based on the longitudinal
628 measure of biomarkers. *Briefings in Bioinformatics* **22**, bbab206 (2021).
- 629 [29] Fu, R. & Gilbert, P. B. Joint modeling of longitudinal and survival data with the Cox
630 model and two-phase sampling. *Lifetime Data Analysis* **23**, 136–159 (2017).

- 631 [30] Ibrahim, J. G., Chen, M.-H. & Sinha, D. Bayesian methods for joint modeling of
632 longitudinal and survival data with applications to cancer vaccine trials. *Statistica Sinica*
633 863–883 (2004).
- 634 [31] Rubin, D. B. *Multiple Imputation for Nonresponse in Surveys* (Wiley, 1987).
- 635 [32] Ramasamy, M. N. *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
636 administered in a prime-boost regimen in young and old adults (COV002): a single-blind,
637 randomised, controlled, phase 2/3 trial. *The Lancet* **396**, 1979–1993 (2020).
- 638 [33] Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
639 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South
640 Africa, and the UK. *The Lancet* **397**, 99–111 (2021).
- 641 [34] Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster
642 dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled
643 analysis of four randomised trials. *The Lancet* **397**, 881–891 (2021).
- 644 [35] Flaxman, A. *et al.* Reactogenicity and immunogenicity after a late second dose or a third
645 dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials
646 (COV001 and COV002). *The Lancet* **398**, 981–990 (2021).
- 647 [36] Henderson, R., Diggle, P. & Dobson, A. Joint modelling of longitudinal measurements and
648 event time data. *Biostatistics* **1**, 465–480 (2000).
- 649 [37] Nordström, P., Ballin, M. & Nordström, A. Risk of infection, hospitalisation, and death up
650 to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population
651 cohort study in Sweden. *The Lancet* **399**, 814–823 (2022).
- 652 [38] Kahn, R., Schrag, S. J., Verani, J. R. & Lipsitch, M. Identifying and alleviating bias due
653 to differential depletion of susceptible people in postmarketing evaluations of COVID-19
654 vaccines. *American Journal of Epidemiology* **191**, 800–811 (2022).
- 655 [39] Williams, L. R. *et al.* Implementation and adherence to regular asymptomatic testing in a
656 COVID-19 vaccine trial. *medRxiv* 2024–02 (2024).
- 657 [40] Amirthalingam, G. *et al.* Serological responses and vaccine effectiveness for extended
658 COVID-19 vaccine schedules in england. *Nature Communications* **12**, 7217 (2021).
- 659 [41] Aldridge, R. W. *et al.* SARS-CoV-2 antibodies and breakthrough infections in the Virus
660 Watch cohort. *Nature Communications* **13**, 4869 (2022).
- 661 [42] Emary, K. R. *et al.* Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against
662 SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a
663 randomised controlled trial. *The Lancet* **397**, 1351–1362 (2021).

- 664 [43] Li, N., Elashoff, R. M. & Li, G. Robust joint modeling of longitudinal measurements and
665 competing risks failure time data. *Biometrical Journal: Journal of Mathematical Methods*
666 *in Biosciences* **51**, 19–30 (2009).
- 667 [44] White, I. R. & Royston, P. Imputing missing covariate values for the Cox model. *Statistics*
668 *in Medicine* **28**, 1982–1998 (2009).
- 669 [45] Stan Development Team. *Stan Modeling Language Users Guide and Reference Manual*
670 (2022). URL <https://mc-stan.org>.
- 671 [46] Vehtari, A., Gelman, A., Simpson, D., Carpenter, B. & Bürkner, P.-C.
672 Rank-normalization, folding, and localization: an improved R for assessing convergence of
673 MCMC (with discussion). *Bayesian Analysis* **16**, 667–718 (2021).
- 674 [47] Sinha, D., Ibrahim, J. G. & Chen, M.-H. A Bayesian justification of Cox’s partial
675 likelihood. *Biometrika* **90**, 629–641 (2003).
- 676 [48] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation
677 for Statistical Computing, Vienna, Austria (2023). URL <https://www.R-project.org/>.
- 678 [49] RStudio Team. *RStudio: Integrated Development Environment for R*. RStudio, PBC.,
679 Boston, MA (2020). URL <http://www.rstudio.com/>.
- 680 [50] Therneau, T. M. *A Package for Survival Analysis in R* (2024). URL
681 <https://CRAN.R-project.org/package=survival>. R package version 3.6-4.
- 682 [51] Stan Development Team. RStan: the R interface to Stan (2024). URL
683 <https://mc-stan.org/>. R package version 2.32.6.
- 684 [52] Knaus, J. *snowfall: Easier Cluster Computing (Based on 'snow')* (2023). URL
685 <https://CRAN.R-project.org/package=snowfall>. R package version 1.84-6.3.
- 686 [53] Wickham, H. *ggplot2: Elegant Graphics for Data Analysis* (Springer-Verlag New York,
687 2016). URL <https://ggplot2.tidyverse.org>.
- 688 [54] Neuwirth, E. *RColorBrewer: ColorBrewer Palettes* (2022). URL
689 <https://CRAN.R-project.org/package=RColorBrewer>. R package version 1.1-3.
- 690 [55] Wickham, H., Vaughan, D. & Girlich, M. *tidyr: Tidy Messy Data* (2024). URL
691 <https://CRAN.R-project.org/package=tidyr>. R package version 1.3.1.

692 Acknowledgements

693 We thank Geoff Nicholls for a helpful discussion suggesting the use of Bayesian cut posteriors,
694 which led us to developing the Bayesian multiple imputation method.

695 **Author contributions**

696 All authors contributed to the conceptualisation of the study. SF, AJP and MV contributed to
697 data collection. DJP, MDC and DS developed the statistical methods. DJP conducted the
698 statistical analysis. The project was jointly supervised by MDC and DS. The first draft of the
699 report was written by DJP and reviewed by MDC and DS. All authors critically reviewed and
700 approved the final version.

701 **Funding**

702 The collection of the data used in this work was supported by the UK Research and Innovation
703 (MC_PC_19055), Engineering and Physical Sciences Research Council (EP/R013756/1),
704 National Institute for Health Research (COV19 OxfordVacc-01), Coalition for Epidemic
705 Preparedness Innovations (Outbreak Response To Novel Coronavirus (COVID-19)), National
706 Institute for Health Research Oxford Biomedical Research Centre (BRC4 Vaccines Theme),
707 Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China (2018-I2M-2-
708 002), Thames Valley and South Midlands NIHR Clinical Research Network. DJP discloses
709 support for the research of this work from the Engineering and Physical Sciences Research
710 Council (EP/W523781/1). The views expressed in this publication are those of the authors and
711 not necessarily those of the NIHR or the UK Department of Health and Social Care.
712 AstraZeneca reviewed the final manuscript but the academic authors retained editorial control.
713 Other funders had no role in study design, data collection and analysis, or decision to publish.

714 **Competing interests**

715 SF, AJP and MV are contributors to intellectual property licensed by Oxford University
716 Innovation to AstraZeneca. AJP is Chair of the UK Department of Health and Social Care's
717 (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in
718 discussions on COVID-19 vaccines. The authors report no other conflicts of interest.

719 **Ethics approval**

720 The COV002 study was approved in the United Kingdom by the Medicines and Healthcare
721 products Regulatory Agency (MHRA), reference 21584/0428/001 0001, and the South-Central
722 Berkshire Research Ethics Committee, reference 20/SC/0179. All participants provided
723 informed consent.

⁷²⁴ **Materials & Correspondence**

⁷²⁵ Correspondence to Daniel J. Phillips, email: daniel.phillips@stats.ox.ac.uk.